Elizabeta Nemeth is a Professor of Medicine at the David Geffen School of Medicine at UCLA, and Director of the UCLA Center for Iron Disorders. Dr. Nemeth received her BS in Molecular Biology at the University of Belgrade, Yugoslavia, and a PhD in Cell, Molecular and Neurosciences at the University of Hawaii. Dr. Nemeth came to UCLA for a postdoctoral fellowship in 2002, and has been studying the pathobiology of the iron-regulatory peptide hepcidin ever since. She has made major contributions to the understanding of iron homeostasis and of its dysregulation in many diseases. She characterized the regulation of hepcidin production by inflammation and iron, and elucidated the mechanism of action of hepcidin in regulating the absorption of dietary iron and its release from stores. Dr. Nemeth also described the role of hepcidin in various iron disorders including hereditary hemochromatosis, iron-loading anemias (e.g. β-thalassemia), and iron-restricted anemias associated with inflammation and chronic kidney disease. In 2007, Dr. Nemeth received the Grace Goldsmith Award from the American College of Nutrition for "significant achievements in the field of nutrition by a scientist under the age of 50 years". Dr. Nemeth’s laboratory has been continuously funded by the National Institute of Health and grants from biotechnology sector. Dr. Nemeth is currently serving as a standing member of the Molecular and Cellular Hematology Study Section of the National Institutes of Health, a member of the Board of Directors of the International Bioiron Society, and a member of the Editorial Board of Blood. She helped start three biotechnology companies: Intrinsic LifeSciences, focused on developing iron diagnostics, Merganser Biotech, focused on developing hepcidin peptide therapeutics, and Silarus Therapeutics, focused on developing erythroferrone-targeted therapeutics.